Your browser doesn't support javascript.
Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study.
Euden, Joanne; Pallmann, Philip; Grozeva, Detelina; Albur, Mahableshwar; Bond, Stuart E; Brookes-Howell, Lucy; Dark, Paul; Hellyer, Thomas; Hopkins, Susan; Howard, Philip; Llewelyn, Martin J; Maboshe, Wakunyambo; McCullagh, Iain J; Ogden, Margaret; Parsons, Helena; Partridge, David; Powell, Neil; Shaw, Dominick; Shinkins, Bethany; Szakmany, Tamas; Todd, Stacy; Thomas-Jones, Emma; West, Robert M; Carrol, Enitan D; Sandoe, Jonathan A T.
  • Euden J; Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF14 4EP, UK.
  • Pallmann P; Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF14 4EP, UK.
  • Grozeva D; Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF14 4EP, UK.
  • Albur M; Severn Infectious Sciences, Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB, UK.
  • Bond SE; Medicines Optimisation and Pharmacy Services, Pindersfield Hospital, Mid Yorkshire Hospitals NHS Trust, Wakefield WF1 4DG, UK.
  • Brookes-Howell L; Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF14 4EP, UK.
  • Dark P; Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK.
  • Hellyer T; Critical Care Department, Royal Victoria Infirmary, The Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
  • Hopkins S; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
  • Howard P; UK Health Security Agency, London SW1P 3JR, UK.
  • Llewelyn MJ; School of Healthcare, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK.
  • Maboshe W; Department of Pharmacy and Medicines Optimisation, NHS England, Leeds LS2 7UE, UK.
  • McCullagh IJ; Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton BN1 9PS, UK.
  • Ogden M; Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF14 4EP, UK.
  • Parsons H; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
  • Partridge D; Perioperative and Critical Care Department, Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK.
  • Powell N; Public and Patient Involvement Representative, NIHR, London SW1A 2NS, UK.
  • Shaw D; Department of Microbiology, Laboratory Medicine, Northern General Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield S5 7AU, UK.
  • Shinkins B; Department of Microbiology, Laboratory Medicine, Northern General Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield S5 7AU, UK.
  • Szakmany T; Pharmacy Department, Royal Cornwall Hospital, Royal Cornwall Hospitals NHS Foundation Trust, Truro TR1 3LJ, UK.
  • Todd S; Nottingham NIHR Respiratory BRC, University of Nottingham, Nottingham NG5 1PB, UK.
  • Thomas-Jones E; Leeds Institute of Health Sciences, University of Leeds, Leeds LS2 9TJ, UK.
  • West RM; Critical Care Directorate, Grange University Hospital, Aneurin Bevan University Health Board, Cwmbran NP44 2XJ, UK.
  • Carrol ED; Tropical and Infectious Disease Unit, The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool L7 8XP, UK.
  • Sandoe JAT; Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF14 4EP, UK.
Methods Protoc ; 5(6)2022 Nov 28.
Article in English | MEDLINE | ID: covidwho-2123765
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus responsible for the coronavirus disease 2019 (COVID-19) pandemic. Although COVID-19 is a viral illness, many patients admitted to hospital are prescribed antibiotics, based on concerns that COVID-19 patients may experience secondary bacterial infections, and the assumption that they may respond well to antibiotic therapy. This has led to an increase in antibiotic use for some hospitalised patients at a time when accumulating antibiotic resistance is a major global threat to health. Procalcitonin (PCT) is an inflammatory marker measured in blood samples and widely recommended to help diagnose bacterial infections and guide antibiotic treatment. The PEACH study will compare patient outcomes from English and Welsh hospitals that used PCT testing during the first wave of the COVID-19 pandemic with those from hospitals not using PCT. It will help to determine whether, and how, PCT testing should be used in the NHS in future waves of COVID-19 to protect patients from antibiotic overuse. PEACH is a retrospective observational cohort study using patient-level clinical data from acute hospital Trusts and Health Boards in England and Wales. The primary objective is to measure the difference in antibiotic use between COVID-19 patients who did or did not have PCT testing at the time of diagnosis. Secondary objectives include measuring differences in length of stay, mortality, intensive care unit admission, and resistant bacterial infections between these groups.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: Mps5060095

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: Mps5060095